<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36546382</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-7488</ISSN><JournalIssue CitedMedium="Internet"><Volume>123</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>The American journal of nursing</Title><ISOAbbreviation>Am J Nurs</ISOAbbreviation></Journal><ArticleTitle>New Drug Approved For ALS.</ArticleTitle><Pagination><StartPage>22</StartPage><EndPage>23</EndPage><MedlinePgn>22-23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/01.NAJ.0000911516.31267.67</ELocationID><Abstract><AbstractText>Sodium phenylbutyrate-taurursodiol (Relyvrio) has been approved to treat amyotrophic lateral sclerosis.The drug was approved despite the absence of phase 3 clinical trial data. Data from a small phase 2 trial indicated that patients receiving Relyvrio had a slower loss of functioning than those taking placebo.Relyvrio poses a risk to patients who are sensitive to salt intake and to those with pancreatic, intestinal, and enterohepatic circulation disorders.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aschenbrenner</LastName><ForeName>Diane S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch : diane.aschenbrenner@gmail.com .</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Nurs</MedlineTA><NlmUniqueID>0372646</NlmUniqueID><ISSNLinking>0002-936X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000723627">sodium phenylbutyrate and taurursodiol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>22</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36546382</ArticleId><ArticleId IdType="doi">10.1097/01.NAJ.0000911516.31267.67</ArticleId><ArticleId IdType="pii">00000446-202301000-00012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mehta P, et al. Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies, 2017. Amyotroph Lateral Scler Frontotemporal Degener 2022 Apr. 15. Online ahead of print.</Citation></Reference><Reference><Citation>Lowe D. A new ALS drug. Science 2022 Mar 29. https://www.science.org/content/blog-post/new-als-drug .</Citation></Reference><Reference><Citation>Belluck P. Price of new A.L.S. treatment will be $158,000 per year, maker says. New York Times 2022 Sep 30. https://www.nytimes.com/2022/09/30/health/relyvrio-price-als-amylyx.html .</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>